-12.1%
DOW vs MRNA
+855.4%
-867.5%
-64.4%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -4.0% | -2.2% | -1.9% | -4.0% |
| 7D | -12.1% | -12.7% | +0.6% | -11.8% |
| 30D | -4.4% | -20.7% | +16.2% | -4.0% |
| 3M | -10.7% | +46.3% | -57.0% | -12.1% |
| 6M | -18.2% | +305.2% | -323.4% | -25.0% |
| YTD | +28.4% | +561.2% | -532.9% | +13.8% |
| 1Y | +45.4% | +772.1% | -726.7% | +26.8% |
| 3Y | -33.2% | +147.0% | -180.2% | -39.8% |
| 5Y | -33.4% | -26.1% | -7.4% | -39.8% |
| All | -12.1% | +855.4% | -867.5% | -15.4% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling